The IMID Forum

In this edition, recorded at ACR 2019, real-world tofacitinib safety data is presented by Professor Kremer and the impact of baricitinib and tofacitinib on pain is analysed by Professors Taylor and Dougados

In this edition experts, including Professor Smolen and Professor McInnes, present the latest data for the recently approved JAK inhibitor, upadacitinib. The presentations include: data from the SELECT trials, safety analyses, switching from TNF inhibitors, and the mode of action of upadacitinib.

Professor Calabrese introduces highlights from Day 4 of ACR 2019

Professor Calabrese introduces highlights from Day 3 of ACR 2019

Professor Calabrese presents highlights from Day 2 of ACR 2019

Professor Kevin Winthrop introduces the key abstracts from Day 1 at ACR 2019

Professor McInnes presents the monthly podcast reviewing a paper by Professor Bruno Fautrel and another paper by Professor Christina Charles-Schoeman.

Prof McInnes presents the monthly podcast reviewing a paper he authored along with colleagues and another paper by Dr Mori Shunsuke.

Professor Nash Interviews Professor Fleischmann from the University of Texas Southwester Medical Center, about his two recently published papers on upadacitinib.

Professor Nash Interviews Professor Leonard Calabrese from the RJ Fasenmyer Center for clinical Immunology, about his paper examining the live zoster vaccine in patients treated with tofacitinib monotherapy, tofacitinib with MTX and adalimumab with MTX.